- Home
- IGMS vs ANL Comparison
IGMS vs ANL Comparison
Compare IGMS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ANL
- Stock Information
- Founded
- IGMS 1993
- ANL 2004
- Country
- IGMS United States
- ANL Cayman Islands
- Employees
- IGMS N/A
- ANL N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- IGMS Health Care
- ANL
- Exchange
- IGMS Nasdaq
- ANL Nasdaq
- Market Cap
- IGMS 82.1M
- ANL 79.0M
- IPO Year
- IGMS 2019
- ANL 2023
- Fundamental
- Price
- IGMS $1.22
- ANL $1.71
- Analyst Decision
- IGMS Hold
- ANL Strong Buy
- Analyst Count
- IGMS 8
- ANL 2
- Target Price
- IGMS $6.14
- ANL $9.00
- AVG Volume (30 Days)
- IGMS 167.6K
- ANL 5.0K
- Earning Date
- IGMS 05-07-2025
- ANL 04-29-2025
- Dividend Yield
- IGMS N/A
- ANL N/A
- EPS Growth
- IGMS N/A
- ANL N/A
- EPS
- IGMS N/A
- ANL N/A
- Revenue
- IGMS $2,679,000.00
- ANL $5,000,000.00
- Revenue This Year
- IGMS $121.76
- ANL N/A
- Revenue Next Year
- IGMS $46.83
- ANL N/A
- P/E Ratio
- IGMS N/A
- ANL N/A
- Revenue Growth
- IGMS 25.77
- ANL N/A
- 52 Week Low
- IGMS $0.92
- ANL $1.71
- 52 Week High
- IGMS $22.50
- ANL $15.55
- Technical
- Relative Strength Index (RSI)
- IGMS 47.65
- ANL 35.13
- Support Level
- IGMS $1.16
- ANL $1.82
- Resistance Level
- IGMS $1.31
- ANL $2.16
- Average True Range (ATR)
- IGMS 0.12
- ANL 0.11
- MACD
- IGMS 0.03
- ANL -0.02
- Stochastic Oscillator
- IGMS 76.92
- ANL 3.92
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.